Background. Streptococcus pneumoniae causes a substantial proportion of community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP) in the United States. Limited data are available regarding the pneumococcal serotypes causing CAP and HCAP.
Pneumonia and influenza combined represent the eighth most common cause of death in the United States and the leading cause of death from infectious disease [1] .
An estimated 4 million cases of community-acquired pneumonia (CAP) occur annually in the United States, resulting in >1 million hospitalizations and substantial morbidity and mortality, particularly among older adults [2] .
It has been estimated that 17%-41% of CAP and 6%-10% of healthcare-associated pneumonia (HCAP) cases in the United States are caused by Streptococcus pneumoniae [3, 4] , with the rate of S. pneumoniae isolation increasing when more invasive methods are used for obtaining specimens [5] . Compared with S. pneumoniaenegative cases, S. pneumoniae-related CAP is associated with poorer patient outcomes, including increased incidence of bacteremia, septic shock, need for mechanical ventilation, and mortality [6] . Pneumococcal pneumonia can be subdivided into invasive (bacteremic) and noninvasive (nonbacteremic) cases, the latter responsible for the majority of disease. Estimates suggest that approximately 500 000 cases of noninvasive pneumonia occur annually in the United States in adults aged ≥50 years, causing nearly 20 000 deaths [7, 8] .
A 7-valent pneumococcal conjugate vaccine (PCV7) has been available in the United States for use in children aged <5 years since 2000, providing protection against S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the pediatric immunization program; PCV13 includes all the serotypes contained in PCV7 plus the additional serotypes 1, 3, 5, 6A, 7F, and 19A. Numerous studies have shown that the inclusion of PCV7 in the routine infant immunization schedule in the United States, has led to major reductions in vaccine serotype-associated invasive pneumococcal disease (IPD) in both infants and unvaccinated older populations [9] [10] [11] . Similar trends for IPD reduction are also becoming apparent for the additional serotypes in the more recently introduced PCV13 vaccine [12] .
Culture methods are of limited value for detecting noninvasive pneumococcal disease for several reasons, including the nature of the infection and the difficulty obtaining sputum samples of sufficient quality to aid diagnosis. Therefore, the distribution of the S. pneumoniae serotypes in adults presenting with noninvasive CAP and HCAP is poorly understood. Binax-NOW®, a commercially available S. pneumoniae assay, can detect the C-polysaccharide from S. pneumoniae in the urine of subjects with a diagnosis of pneumonia. However, this assay is not serotype specific.
Several investigators [13, 14] have recently reported on serotype-specific urine antigen detection (UAD) assays that, for the first time, allow determination of the serotype distribution in both invasive and noninvasive pneumonia cases. Bewick et al [13] evaluated the S. pneumoniae serotype distribution in patients with noninvasive CAP within the catchment area of 2 large teaching hospitals in the United Kingdom (including approximately 600 000 adults), using a urinary immunoassay capable of detecting 14 pneumococcal serotypes, including those associated with the PCV7 and PCV13 vaccines. PCV7-associated serotypes were identified in 19.7% of pneumococcal CAP cases, and PCV13-associated serotypes in 57.4% [13] .
The primary objective of this study was to estimate the proportion of adults aged ≥50 years presenting to participating US hospitals with radiographically confirmed CAP or HCAP who had the S. pneumoniae serotypes contained in PCV13. This was done using a UAD diagnostic assay that can simultaneously detect PCV13 serotype-specific S. pneumoniae polysaccharides secreted in human urine [14] . A secondary objective was to describe the serotype distribution among S. pneumoniaepositive patients.
METHODS

Study Design
This was a prospective, cross-sectional, multicenter study based on a convenience sample drawn from 13 geographically dispersed sites across the United States. Individual sites participated in the study for 2-20 months and were located in Allentown, Pennsylvania; Norfolk, Virginia; San Antonio, Texas; Akron, Ohio; Detroit, Michigan (2 sites); San Diego, California; Worcester, Massachusetts; Mobile, Alabama; Tampa, Florida; Chicago, Illinois; Springfield, Massachusetts; and Las Vegas, Nevada. Two protocol amendments during the study added additional sites, permitted subjects with HCAP into the study, and allowed imaging other than chest radiography to be used as a diagnostic tool. This study was conducted in accordance with applicable laws and regulations, including but not limited to the International Conference on Harmonisation Guideline for Good Clinical Practice and the ethical principles of the Declaration of Helsinki. All included subjects provided informed consent.
Participants
Between February 2010 and September 2011, adults aged ≥50 years presenting at outpatient departments or emergency departments of participating hospitals with signs or symptoms and radiographic evidence of pneumonia, were screened for inclusion in this study. To be included, subjects must have met all of the following criteria: age ≥50 years; presentation to a study site with clinically suspected pneumonia; a finding consistent with pneumonia at chest radiograph, computed tomography, or other imaging modality; and willingness and ability to provide a urine sample. Subjects were excluded if they were transferred to a participating hospital after already having been hospitalized for ≥48 hours at another inpatient facility (ie, a community hospital); had hospital-acquired pneumonia (defined as pneumonia developing 48 hours after hospital admission); or had been previously enrolled in this study within the past 30 days.
Subjects were required to participate for approximately 1 day. Final diagnosis and all-cause mortality data were collected up to 10 days after enrollment. Demographic information, history of exposure to healthcare facilities, history of immunization with 23-valent pneumococcal polysaccharide vaccine (PPSV23), and relevant medical history were recorded. Urine samples were collected noninvasively. If a bladder catheter had been placed as part of routine medical care, a urine sample could be collected from the bag providing it had not been in the bag for >8 hours. Results of blood cultures and respiratory cultures (including sputum, tracheal aspirate, bronchial washings, and pleural fluid) performed per site-specific standard of care were recorded on the case report form.
Definitions
S. pneumoniae-positive CAP or HCAP was defined as radiographically confirmed pneumonia with ≥1 positive results from the UAD assay, BinaxNOW® S. pneumoniae assay, or bacterial (blood or respiratory) culture from any site, which fulfilled the criterion for CAP or HCAP. HCAP was defined as pneumonia in a subject with exposure to a healthcare facility including a dialysis center, chronic treatment clinic, nursing home, longterm care facility, hospital, assisted-living facility, or other facility, within 3 months before enrollment.
Analyses
Two aliquots of the urine sample were frozen and stored for subsequent shipment to the central laboratory (Pfizer Vaccines Research East and Early Development) for S. pneumoniae UAD assay testing as described elsewhere [14] . This assay detects S. pneumoniae serotypes 1, 3, 4, 5, 6A/C, 6B, 7F/A, 9V/ A, 14, 18 (C/A, B, F), 19A, 19F, and 23F [14] . Urine was tested locally using the commercially available BinaxNOW® S. pneumoniae antigen test (Inverness Medical; now marketed by Alere North America). S. pneumoniae isolates from cultures were sent to a second central laboratory for serotyping using the Quellung reaction (Quest Diagnostics).
Analysis Populations
Evaluable populations were based on all subjects with a final diagnosis consistent with radiographically confirmed pneumonia. For each of the 3 tests (UAD, BinaxNOW® S. pneumoniae, and bacterial cultures), the analysis populations included all subjects who had data for that test. Distribution of PCV13-associated serotypes was assessed in subjects with determinate UAD assay or bacterial culture data. Evaluation included the presence of comorbid conditions that put the subject at risk for pneumonia (chronic obstructive pulmonary disease, asthma, congestive heart failure, coronary artery disease, chronic kidney disease, and diabetes mellitus) or at high risk (eg, immunocompromised) for pneumonia (autoimmune disease, immunodeficiency, human immunodeficiency virus, AIDS, cancer, and organ transplant). Subjects with significant protocol violations or indeterminate data for a given assay were not included in the final analysis.
Statistical Analyses
All analyses performed in this study were descriptive. For results reported as proportions of subjects with positive results, corresponding 95% confidence intervals were also reported.
RESULTS
Study Subjects
In this study, 788 subjects consented to participate of whom 7 were excluded for protocol violations or screening failures, and 781 were enrolled. Of those enrolled, 710 subjects had radiographically confirmed pneumonia. The demographic and clinical characteristics of this population are shown in Table 1 . Their median age was 65.4 years (range, 50-102 years); 54.2% were male, and 96.6% were hospitalized at this visit for this episode of pneumonia, with 10.9% admitted to an intensive care unit (ICU). Overall, 49.2% of subjects were aged 50 to <65 years, 22.3% 65 to <75 years, and 28.6% ≥75 years. Seven enrolled subjects died during the study, for an overall all-cause mortality rate of 0.9%. Of these 1 subject with confirmed pneumococcal pneumonia died of septic shock secondary to necrotizing pneumonia.
Results of UAD assay were obtained in 708 subjects with radiographically confirmed pneumonia (99.7%), BinaxNOW® assay results were obtained in the same 708 (99.7%), and microbiology results in 634 (89.3%), of whom 615 (97.0%) had blood cultures.
S. pneumoniae-Positive CAP or HCAP Population
Ninety-eight subjects (13.8%) with S. pneumoniae detected by ≥1 test and radiographically confirmed pneumonia were considered to have S. pneumoniae-positive CAP or HCAP. Overall, 11.0% (78 of 708 subjects) had positive UAD assay results indicating the presence of a PCV13-associated serotype. The proportions of subjects with positive results for S. pneumoniae by BinaxNOW® and bacterial culture were 4.8% (34 of 708 subjects) and 2.2% (14 of 634), respectively. Among 615 subjects with blood cultures performed per site-specific standard of care, only 12 (2.0%) had positive blood cultures for S. pneumoniae. Among these blood culture-positive subjects, 11 (91.7%) had positive UAD results, and 5 (41.7%) had positive BinaxNOW® results. The single isolate with a negative UAD result was not serotyped. Overall 19.2% of the UAD-positive subjects (15 of 78) were also positive by BinaxNOW® assay.
Overall, 60.2% of subjects with S. pneumoniae-positive CAP or HCAP were aged 50 to <65 years. In total, 18.4% of the S. pneumoniae-positive group had HCAP, and the majority of healthcare exposure within the prior 3 months occurred in a hospital. The proportion of subjects who had previously been vaccinated with PPSV23 was similar in the S. pneumoniaepositive and S. pneumoniae-negative groups (40.8% and 44.8%, respectively). Influenza-like illness in the past 30 days, immunodeficiency (including human immunodeficiency virus), current smoker status, and current alcohol or drug abuse were more common among subjects who were S. pneumoniae positive.
Identification of PCV-Associated Serotypes by UAD
A PCV13-associated serotype was detected in 78 (79.6%) of the 98 subjects with S. pneumoniae-positive CAP or HCAP. Of the 78 UAD-positive subjects, 60 (76.9%) had at least 1 comorbid condition that put them at risk or at high risk for pneumonia. The numbers and proportions of subjects at each study site with positive UAD assay results are shown in Table 2 . In total, 84 PCV13-associated serotypes were identified in the 78 subjects by UAD assay; 25.0% were PCV7-associated serotypes, and 75.0% were among the 6 additional serotypes included in PCV13 (Figure 1) .
A PCV7-associated serotype was present in 21 UAD-positive subjects (26.9%), and 1 of the 6 additional serotypes associated with PCV13 was present in 62 UAD-positive subjects (79.5%). Serotype distribution by age, sex, and CAP or HCAP status are shown in Table 3 .
Serotype 19A was the most prevalent of the additional serotypes in PCV13. Serotype 14 was the most prevalent among the PCV7-associated serotypes. Six subjects had 2 PCV13-associated serotypes in the following combinations: serotypes 5 and 23F (n = 1), 5 and 19A (n = 1), 5 and 14 (n = 3), and 19A and 14 (n = 1). At 2 study sites, 4 subjects were positive for the same serotype within a 60-day window; at site 009 (Alabama) 4 subjects were positive for serotype 9V/A, and at site 1013 (Las Vegas) 4 were positive for serotype 18.
Fourteen subjects (2.2%) were positive for S. pneumoniae by bacterial culture (11 by blood culture alone, 2 by sputum culture alone, and 1 by both). Five subjects with invasive disease for whom serotype data were obtained had a PCV13-associated serotype (serotype 1 in 2, 19A in 2, and 7F in 1) and 1 subject was positive for the nonvaccine serotype 6C. Samples from the remaining 8 subjects were not serotyped by the local site. 
DISCUSSION
This study is the first to utilize a serotype-specific UAD assay to assess the distribution of S. pneumoniae vaccine serotypes associated with adult CAP or HCAP in the United States. The use of this UAD assay provided increased sensitivity over previous methods and allowed for better understanding of pneumococcal CAP or HCAP epidemiology and the serotype specificity of the associated disease. In this study S. pneumoniae was detected in 13.8% of subjects with radiographically confirmed pneumonia. This was lower than the 18%-40% prevalence reported in recent studies, including a study performed in the Netherlands using the same UAD assay and a UK study that used a similar serotype-specific S. pneumoniae urinary immunoassay [13, 15, 16] . The prevalence was likely affected by the relative insensitivity of the BinaxNOW® assay; positive in 19.2% of subjects positive by any other test and 42% of the blood culture-positive subjects. With correction for this insensitivity, estimates of pneumococcal contribution in the present study would be 17%-25%. A true decline in pneumococcal CAP and HCAP prevalence in the United States a decade after PCV7 introduction may also have contributed to the lower incidence of pneumococcal disease [10, 17] .
More important, it has been documented elsewhere that pneumococcus is less likely to be identified in less-severe CAP [18] . The S. pneumoniae burden observed in the present study may reflect differences in study design (eg, convenience or opportunistic recruitment strategies and consent procedures) leading to enrollment of subjects with less-severe disease. In the study by Bewick et al, 40% of CAP cases were associated with pneumococcus, but, notably, nearly 60% of subjects had pneumonia severity index class IV or V disease [13, 19] . Although we did not document this index, >80% of subjects were admitted to a general hospital ward, and only 11% had severe enough disease to require ICU admission. Other studies have reported the proportion of CAP linked to S. pneumoniae as 6.5% in patients admitted to general wards (vs 15.2% for ICU patients) and 11% in hospitalized patients with Pneumonia Outcomes Research Team risk class III or IV, both more in line with our findings [18, 20] .
The overall mortality rate in our study was also lower than expected. The relative paucity of data on etiology of noninvasive CAP and potential impact of changes in diagnostic coding or documentation make it difficult to determine whether mortality rates have genuinely changed in recent years [21] . Noting the previously published relationships between ICU admission, increased disease severity, and increased mortality, however, the relatively small proportion of subjects admitted to ICUs may also explain the low mortality rate we observed, compared with other studies [13, 18, 22] .
PCV13 vaccine serotypes were identified by the UAD assay in 11% of the radiographically confirmed pneumonia population. The most surprising finding in the study was the number of subjects in whom PCV7-associated serotypes were detected. The impact of the pediatric PCV7 childhood immunization program on IPD caused by these serotypes in adults is well documented [9] [10] [11] . Pilishvili et al [10] reported that by 2007, 8 years after the introduction of PCV7, rates of IPD due to Figure 1 . Serotypes identified in the 78 subjects by urine antigen detection assay. Abbreviations: PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
PCV7-associated serotypes had been reduced by 87% and 92% in subjects aged 50 to <65 years and ≥65 years, respectively. In 2009, before the start of this study, the proportion of PCV7-associated serotypes observed in IPD in adults aged >50 years was <4%, accounting for approximately 8% of PCV13-associated invasive isolates (including serotype 6C) during that year (M. Moore, personal communication). Recent publications and commentaries have discussed how the PCV13 vaccine and its adoption into the pediatric program might affect invasive and noninvasive pneumococcal disease in adults [23] [24] [25] [26] . However, despite the reductions in PCV7-associated invasive disease, PCV7-associated serotypes made up 25% of 84 S. pneumoniae serotypes identified by UAD assay in the present study. Serotype 14 was the greatest contributor (6 of 78 serotype-positive urine samples), serotypes 9V/A and 23F were each detected in 4 urine samples, and serotype 18 in 5 samples. Overall, 6 of the 7 PCV7-associated serotypes were represented. The lack of PCV7-associated serotypes identified from normally sterile sites may reflect the indirect effect on IPD referenced above [10] .
Despite differences in recruitment methods, duration, and proportion of pneumococcal disease between this work and the study by Bewick et al, it is interesting that PCV7-associated serotypes seem overrepresented in both studies [13] . PCV7 was introduced into the United Kingdom in 2006 and an indirect effect on IPD caused by all PCV7-associated serotypes was detectable in 2008-2010 [12] . Nevertheless, 37% of the PCV13-associated serotype isolates identified by Bewick et al were PCV7-associated serotypes [13] . Similar to the present findings, serotype 14 was the greatest contributor despite the dramatic decrease in IPD linked to this serotype in the United Kingdom at that time (90% reduction in persons aged 5 to <65 years; 84% reduction in those aged >65 years) [12] . Serotype 4 was the next most important PCV7-associated serotype in the UK CAP study [13] .
It has previously been assumed that the serotype distribution measured by IPD surveillance in specific age groups would also represent the serotypes causing noninvasive pneumonia in those same groups [27] . However, our findings and those of Bewick et al suggest that this may not be the case [13] . The underlying explanation for the differences is unknown; however, our data suggest that the indirect effect of the childhood immunization program has reduced the circulation of PCV7-associated serotypes but not eliminated them. There does not seem to be any correlation between the presumed "invasiveness" of a given serotype as determined by Sleeman et al [28] and the prevalence of the mostly noninvasive disease we detected for CAP and HCAP. A second surprising finding was the prevalence of serotype 5, which represented nearly 15% of the PCV13-associated serotype isolates detected by UAD assay. Again, a similar result was seen in the study by Bewick et al, in which approximately 10% of the PCV13-associated serotypes observed were serotype 5. This serotype is rarely found in invasive disease isolates in the United States and United Kingdom, regardless of age group [10, 12] . Serotype 5 is rarely carried in children and generally considered highly invasive [28] .
The prevalence of pneumococcal serotypes would be expected to vary by age and geographic region, and we observed differences among both age groups and sites in this study. Two participating sites reported that pneumococcal CAP or HCAP cases were caused predominantly by 1 individual serotypeserotype 9V/A at 1 site and serotype 18 at the other (both PCV7-associated serotypes). The pneumococcal CAP or HCAP cases related to these serotypes appeared within a 60-day time period at each site. No laboratory errors were identified that would explain these findings. Unfortunately, no further information is available from which to conclude whether these predominant serotypes result from child-to-adult or adult-to-adult transmission [29] .
For adults aged ≥65 years or children and adults aged ≥2 years with chronic illness or other risk factors (ie, immunocompromising conditions, smoking, living in particular environments), PPSV23 has been recommended although controversy persists over its ability to protect against noninvasive pneumococcal pneumonia [9, 30, 31] . Notably, the vaccination rates in our study were similar (approximately 40%) in the S. pneumoniae-positive and S. pneumoniae-negative CAP or HCAP groups. On 30 December 2011, the US Food and Drug Administration approved the use of PCV13 in adults aged ≥50 years for prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes contained in the vaccine [32] . The Advisory Committee on Immunization Practices currently recommends providing PCV13, in addition to PPSV23, to adults aged ≥19 years with certain immunocompromising conditions [33] . In the present study, 36% of the UAD-positive pneumonia cases occurred in patients considered at high risk for pneumonia (eg, immunocompromised individuals).
This study has several limitations. It was conducted using a convenience sample, which may have introduced bias into the screening or recruitment process, thereby limiting the generalizability of the results. Recruitment was limited to adults aged ≥50 years, and the recruitment period varied considerably among sites, with coverage of 1 winter season reducing the potential number of CAP or HCAP cases. The UAD assay cannot detect all S. pneumoniae serotypes. This study was performed soon after the introduction of PCV13 into the pediatric national immunization program, and its findings therefore would not reflect any indirect effects of this vaccine on serotype distribution in adults.
In conclusion, across the geographically dispersed participating sites, 11.0% of subjects with radiographically confirmed pneumonia were positive for PCV13-associated serotypes of S. pneumoniae. The lower-than-expected rate of S. pneumoniae identification may partly reflect the protective effects of the PCV7 and PPSV23 vaccination programs but probably reflects the reduced disease severity in our population compared with other studies. Assessing serotype-specific pneumococcal CAP or HCAP with a UAD assay suggests that the serotypes causing noninvasive CAP or HCAP in adults may differ significantly from those causing invasive disease, with an overrepresentation of serotypes present in the PCV7 vaccine. In addition serotype 5, rarely seen in contemporary surveillance of invasive disease in the United States, was a major contributor to the noninvasive pneumonia cases we observed. Further longitudinal studies are required to monitor the serotype distribution in subjects with CAP or HCAP and the impact of the PCV13 vaccination programs and to investigate the transmission of vaccine serotypes and mechanisms for noninvasive disease progression.
Notes
